Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?

Ionis Pharmaceuticals shares fell 9.24% to close at $28.14. The primary driver was a wave of analyst downgrades following the company’s third-quarter report, which revealed a significant net loss and a sharp reduction in guidance for its lead product, Tryngolza.

What Happened

Ionis reported third-quarter revenue of roughly $243 million, which exceeded estimates, but the stock declined due to a $110 million net loss and a more than 50% cut to Tryngolza guidance. This mixed performance triggered immediate reassessments from major investment banks. RBC Capital lowered its price target to $60 from $85 while maintaining an Outperform rating. Wells Fargo cut its target to $80, and HC Wainwright & Co. reduced its target to $70, both maintaining their positive ratings. TD Cowen also trimmed its target, citing the Tryngolza miss. Additionally, law firms Wolf Popper LLP and SueWallSt announced investigations into potential securities claims on behalf of shareholders. The company also announced it will present at upcoming investor conferences.

What The Data Shows

The stock printed 22 fresh 52-week lows on November 10, 2026, testing the bottom of its 52-week range of $27.75 to $86.74. Over the last eight sessions, the stock has declined 30.2% from $44.39 to $31.00. Fundamentals show a market cap of $6.6 billion with a trailing twelve-month EPS of negative $3.46 and a net margin of negative 64.7%. Revenue has declined 7.4% over the same period. Intraday, the stock opened at $31.15, hit a high of $31.58 at 8:05 AM ET, and bottomed at $28.08 at 11:15 AM ET. Volume so far stands at 1.5 million shares, which is 0.4 times the three-month daily average. Recent insider activity includes two sales totaling $61,000 by executives Shannon L. Devers and Eric Swayze in mid-October.

What To Watch

Investors will monitor the company’s upcoming presentations at investor conferences for further clarity on the Tryngolza launch trajectory. The current coverage breadth includes 34 stories from 14 sources in the last 36 hours, reflecting heightened attention to the stock’s valuation and legal developments.